- Home
- OKYO vs NRXP Comparison
OKYO vs NRXP Comparison
Compare OKYO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- NRXP
- Stock Information
- Founded
- OKYO 2007
- NRXP 2015
- Country
- OKYO United Kingdom
- NRXP United States
- Employees
- OKYO N/A
- NRXP N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- NRXP Health Care
- Exchange
- OKYO Nasdaq
- NRXP Nasdaq
- Market Cap
- OKYO 79.7M
- NRXP 73.7M
- IPO Year
- OKYO 2022
- NRXP N/A
- Fundamental
- Price
- OKYO $1.99
- NRXP $2.34
- Analyst Decision
- OKYO Strong Buy
- NRXP Strong Buy
- Analyst Count
- OKYO 1
- NRXP 5
- Target Price
- OKYO $7.00
- NRXP $31.60
- AVG Volume (30 Days)
- OKYO 118.6K
- NRXP 473.2K
- Earning Date
- OKYO 07-18-2025
- NRXP 11-17-2025
- Dividend Yield
- OKYO N/A
- NRXP N/A
- EPS Growth
- OKYO N/A
- NRXP N/A
- EPS
- OKYO N/A
- NRXP N/A
- Revenue
- OKYO N/A
- NRXP $242,000.00
- Revenue This Year
- OKYO N/A
- NRXP N/A
- Revenue Next Year
- OKYO N/A
- NRXP $395.09
- P/E Ratio
- OKYO N/A
- NRXP N/A
- Revenue Growth
- OKYO N/A
- NRXP N/A
- 52 Week Low
- OKYO $0.90
- NRXP $1.15
- 52 Week High
- OKYO $3.35
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- OKYO 39.72
- NRXP 43.28
- Support Level
- OKYO $1.90
- NRXP $1.99
- Resistance Level
- OKYO $2.54
- NRXP $2.81
- Average True Range (ATR)
- OKYO 0.25
- NRXP 0.20
- MACD
- OKYO -0.06
- NRXP -0.01
- Stochastic Oscillator
- OKYO 6.83
- NRXP 43.29
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.